Study #2025-0042
A Phase 1, first-in-human study of MEN2312, a KAT6 Inhibitor, as monotherapy and in combination in participants with advanced breast cancer
MD Anderson Study Status
Enrolling
Treatment Agent
MEN2312, Elacestrant
Description
This is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced Breast Cancer
Study phase:
Phase I
Physician name:
Jason Mouabbi
Department:
Breast Medical Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.